Results 261 to 270 of about 577,742 (361)

Use of a Foamy‐Virus Vector System to Produce an ‘Off‐the‐Shelf’ Fcγ‐CR‐T Cell Product for the Treatment of Haematological and Solid Tumour Malignancies

Immunology, EarlyView.
Despite the huge success of chimeric antigen receptor (CAR)‐T cells in the treatment of hematologic malignancies, safety concerns have recently been raised in terms of tumorigenesis, relating to the viral vector systems used for product generation, underlying the need for alternative methods for gene modification.
Ioanna Lazana, Emmanouil Simantirakis, Evangelos Kourous, Maria Daniil, Dimitris Ioannou, George Vassilopoulos   +5 more
wiley   +1 more source

Pre-TCR-targeted immunotherapy for T cell acute lymphoblastic leukemia. [PDF]

Nat Immunol
Fuentes P, García-Peydró M, Alcain J, Mosquera M, Cela C, Cifuentes C, Torrebadell M, Isola I, Camós M, Ramírez M, Alarcón B, Toribio ML.   +11 more
europepmc   +1 more source

Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the EBMT PH&G Committee

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This EBMT Practice Harmonisation and Guidelines Committee consensus provides practical recommendations for the selection, timing and conduct of allogeneic transplantation in advanced‐stage mycosis fungoides and Sézary syndrome, aiming to optimize outcomes through early multidisciplinary collaboration and evidence‐based decision‐making.
Gandhi Damaj, Adèle de Masson, Peter Dreger, Ali Bazarbachi, Philipp Berning, Rafael F. Duarte, Christopher P. Fox, Emmanuella Guenova, Olivier Hermine, Charalampia Kyriakou, Alina Tanase, Olivier Tournilhac, Wojiech Jurczak, Imke E. Karsten, Stéphanie Nguyen Quoc, Yasmina Serroukh, Federico Stella, Gerald Wulf, Anna Sureda, Evangelia Papadavid, Pablo L. Ortiz‐Romero, Annalisa Ruggeri, Isabel Sánchez‐Ortega, Julia J. Scarisbrick, Ibrahim Yakoub‐Agha, Francesco Onida, Norbert Schmitz   +26 more
wiley   +1 more source

Correction to "Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients". [PDF]

Hemasphere
europepmc   +1 more source

Rapid Identification of <i>DUX4::IGH</i> Fusion in Acute Lymphoblastic Leukemia. [PDF]

EJHaem
Moritani K, Eguchi-Ishimae M, Tezuka-Kagajo M, Miyamoto M, Iwamoto M, Kawakami S, Nakamura R, Nagai K, Tomomatsu S, Imai T, Ishida Y, Tauchi H, Ishii E, Eguchi M.   +13 more
europepmc   +1 more source

Challenges of Parents While Providing Complex Medical Care at Home to Children With Cancer: A Cross‐Sectional Convergent Mixed Methods Study

Journal of Clinical Nursing, EarlyView.
ABSTRACT Aim To explore challenges parents of children with cancer encounter while providing complex medical care at home. Methods Design: Cross‐sectional convergent mixed‐methods study. Instruments: Questionnaire and open interviews that mirrored and complemented each other.
Rachel Klausner Shyman, Sveta Roberman, Gal Goldstein, Sabaa Masarwe, Amy Solnica, Rachel Yaffa Zisk‐Rony   +5 more
wiley   +1 more source

DBN1‑mediated upregulation of GAB2 facilitates the migration and invasion of T‑cell acute lymphoblastic leukemia cells. [PDF]

Oncol Rep
Sun J, Huang X, Zeng X, Lei Y, He H, Wei Z, Xiao D, Zhang Q, Li X, Zhou F, Shao L.   +10 more
europepmc   +1 more source

Prolonged exposure to artificial light and carcinogenesis: A systematic review of oncostatic mechanisms associated with melatonin pathways

Photochemistry and Photobiology, EarlyView.
Exposure to artificial light at night (ALAN), particularly at blue wavelengths, disrupts circadian rhythms by suppressing melatonin, thereby increasing cancer susceptibility. This systematic review consolidates evidence linking prolonged ALAN exposure to an elevated risk of breast and prostate tumors.
Gabriel Barboza, Jêmina Oliveira, Antônio Ferreira, Renan Lopes, Marli Cupertino   +4 more
wiley   +1 more source

A Rare Case of Acute Lymphoblastic Leukemia in a Four-Month-Old Infant. [PDF]

Cureus
AlSuwaidi N, Ismail R, Otour B.
europepmc   +1 more source

The Changing Epidemiology of Breakthrough Invasive Fungal Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the Era of Modified‐Release Posaconazole Prophylaxis

Transplant Infectious Disease, EarlyView.
This single‐center retrospective cohort study on 300 allogeneic hematopoietic stem cell transplant recipients from January 2017 to May 2020, in which posaconazole modified release was the most common primary antifungal prophylaxis, demonstrated a breakthrough invasive fungal disease (bIFD) rate of 9%, with associated significant all‐cause mortality at ...
Shio Yen Tio, Chin Fen Neoh, David Ritchie, Lynette Chee, David C. M. Kong, Leon J. Worth, Michelle K. Yong, Monica A. Slavin   +7 more
wiley   +1 more source